NGeneBio

NGeneBio Co., Ltd. is a leading Korean molecular diagnostics (MDx) and companion diagnostics (CDx) company, recognized as the first in Korea to commercialize an NGS-based precision diagnostics platform. The company develops and provides next-generation sequencing (NGS) diagnostic panels and bioinformatics software for cancer and other diseases. Its flagship product, NGeneAnalySys™, is a precision diagnostic platform for cancer comprising genetic diagnostic panels and data analysis tools, while HEMEaccuTest™ is Asia's first CE-IVD certified blood cancer NGS panel. NGeneBio is expanding toward a multimodal, AI-driven precision diagnostics platform that integrates clinical, genomic, pathological, and imaging data to support personalized patient care. The company serves hospitals across Korea and is expanding internationally, with partnerships in Southeast Asia including Thailand and Vietnam.